IP Library Granted Patent US 7,125,677
Granted Patent B2
US 7,125,677 · App. 10/687,361 · Granted Oct 24, 2006

NIMA interacting proteins

Assignee: The Salk Institute for Biological Studies
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,125,677
App. No.
10/687,361
Granted
Oct 24, 2006
Kind
B2
Abstract

A novel class of NIMA interacting proteins (PIN), exemplified by Pin1, is provided. Pin1 induces a G2 arrest and delays NIMA-induced mitosis when overexpressed, and triggers mitotic arrest and DNA fragmentation when depleted. Methods of identifying other Pin proteins and Pin-interacting proteins and identifying compositions which affect Pin activity or expression are also provided.

Claims (7)

1. A method of detecting Pin1 protein in a cell sample, comprising contacting a cell sample with an antibody that selectively binds to a Pin1 protein having the amino acid sequence as set forth in SEQ ID NO: 2, and determining whether said antibody binds to said cell sample, wherein binding of said antibody to said cell sample is indicative of the presence of Pin1 protein in said cell sample.

2. The method of claim 1 , wherein said cell sample comprises a cell, tissue, biological fluid or component thereof suspected of containing a Pin1 protein.

3. The method of claim 1 , wherein said cell sample comprises a human cell sample.

4. The method of claim 3 , wherein said cell sample comprises a hyperproliferative cell.

5. The method of claim 4 , wherein said hyperproliferative cell is from a cancer.

6. The method of claim 5 , wherein said cancer is selected from the group consisting of lung cancer, breast cancer, lymphoid cancer, cancer of the gastrointestinal, genito-urinary tract, adenocarcinoma, colon cancer, renal-cell carcinoma, prostate cancer, leukemia, non-small cell carcinoma of the lung, cancer of the small intestine, and cancer of the esophagus.

7. The method of claim 4 , further comprising detecting a difference in the amount of specific binding of said antibody to said hyperproliferative cell sample as compared to an amount of specific binding of said Pin1 antibody to a normal cell sample.

Assignments (1)
CONFIRMATORY LICENSE Recorded Mar 19, 2015
From: SALK INSTITUTE FOR BIOLOGICAL STUDIES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035223/0905 →
Continuity (5)
Continuation 1061641000 · Jul 8, 2003
Continuation 0927590000 · Mar 24, 1999
Division 0906607400 · Apr 24, 1998
Division 0855591200 · Nov 13, 1995
Related Publication 20040101896A1 · May 27, 2004